Spero Therapeutics, based in Cambridge, Massachusetts, develops treatments for multi-drug resistant infections and rare diseases, with key products including SPR720, tebipenem HBr, and SPR206. The company went public on November 2, 2017, and employs 46 people.
Spero Therapeutics (SPRO) reported a negative EPS surprise in its most recent quarterly earnings. For the most recent quarter, Spero Therapeutics's actual EPS was -$0.38, missing the estimate of -$0.32 per share, resulting in a -20.18% surprise.
📡️ Health Care
Earnings Surprise
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
